New Key Statistics Module, Z-Score and F-Score
NAS:CYCC Key Ratios
| Market Cap $ M | 2.44 |
| Enterprise Value $ M | -0.78 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 3.25 |
| Price/Sales | 3.70 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -26.75 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | 43.10 |
| 5-y EBITDA Growth Rate % | 34.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.03 |
| EV-to-EBITDA | 0.03 |
| PEG | -- |
| Shares Outstanding M | 1.32 |
| Net Margin (%) | -5,370.24 |
| Operating Margin % | -6,060.24 |
| Pre-tax Margin (%) | -6,083.57 |
| Quick Ratio | 0.91 |
| Current Ratio | 0.91 |
| ROA % (ttm) | -128.37 |
| ROE % (ttm) | -227.33 |
| ROIC % (ttm) | -862.97 |
| Dividend Yield % | -- |
| Altman Z-Score | -77.54 |
| Piotroski F-Score | 3.00 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA y-y | N |
| Cash flow > Earnings | Y |
| Lower Leverage y-y | Y |
| Higher Current Ratio y-y | N |
| Less Shares Outstanding y-y | N |
| Gross Margin Increase y-y | N |
| Higher Asset Turnover y-y | Y |
CYCC Number of Guru Trades
CYCC Volume of Guru Trades
Gurus Latest Trades with NAS:CYCC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CYCC is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Cyclacel Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:CYCC
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers